BridgeBio Pharma
BBIO
BBIO
178 hedge funds and large institutions have $1.45B invested in BridgeBio Pharma in 2022 Q1 according to their latest regulatory filings, with 43 funds opening new positions, 49 increasing their positions, 59 reducing their positions, and 57 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
25% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 57
39% less capital invested
Capital invested by funds: $2.37B → $1.45B (-$913M)
Holders
178
Holding in Top 10
4
Calls
$10.2M
Puts
$4.17M
Top Buyers
| 1 | +$57.7M | |
| 2 | +$12.4M | |
| 3 | +$12.3M | |
| 4 |
Morgan Stanley
New York
|
+$7.74M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$7.06M |
Top Sellers
| 1 | -$33.4M | |
| 2 | -$16.7M | |
| 3 | -$12.7M | |
| 4 |
Rockefeller Capital Management
New York
|
-$10.3M |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$8.24M |